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Sodium benzenesulfinate is used widely in the preparation of sulfone, which plays an 
important role in organic synthesis. However the use of polymer-bound sodium 
benzenesulfinate resin in solid phase synthesis has received little attention and thus has 
much scope for exploration. In this thesis, we are interested in developing polymer-bound 
sodium benzenesulfinate as a traceless linker for heterocyclic synthesis.  
 
Heterocyclic compounds have been used widely as therapeutic agents and they also can 
offer high degree of structural diversity. Although large numbers of heterocycles have 
been synthesized on solid phase, there are still many bioactive heterocyclic templates that 
have not been synthesized on solid support in a traceless manner. These include 2-
pyridones, tetrasubstituted imidazoles and 1,2,3,4-tetrahydro-pyrimidine. Hence the goal 
of this thesis is to devise a traceless synthetic strategy to synthesize these potentially 
bioactive heterocycles using polymer bound sodium benezenesulfinate as a linker. 
 
The first library of heterocycles we synthesized is 2-pyridones. This class of compounds 
is of interest as various 2-pyridones have been shown to exhibit various antitumour, 
antibacterial and herbicidal activities. The key steps in our synthesis include (i) sulfinate 
S-alkylation, (ii) sulfone anion alkylation with an epoxide, (iii) γ-hydroxyl sulfone  γ-
ketosulfone oxidation, and (iv) traceless product release by a one-pot elimination-
cyclization process. Fifteen compounds were prepared in 20-49% overall yield. 
 
 vi
The second library we prepared is the 1,2,4,5-tetrasubstituted imidazoles. Several 
members of this class of compounds have been shown to possess antifungal and 
antibacterial activities. Key steps involved are (i) sulfinate acidification, (ii) sulfinic acid 
condensation with aldehyde and amine, and (iii) traceless product release by a one-pot 
elimination-cyclization reaction. Elimination reaction was carried out in the presence of a 
thiazolium catalyst which facilitated the in situ formation of the α-ketoamide which was 
subsequently converted to the corresponding 1,3-azole by treatment with amines, PPh3/I2 
or Lawesson’s reagent.  Eighteen compounds were obtained in 19-39% overall yields. 
 
The third library we prepared is the 3,4-dihydropyrimidine-2-ones, which is a template 
found in various anticonvulsant, insecticidal, analgesic, antiproteolytic, antitumor and 
antibacterial agents. Key steps in the synthesis are (i) sulfinate acidification, (ii) 
condensation of urea or thiourea with aldehydes and sulfinic acid, and (iii) traceless 
product release by a one-pot cyclization-dehydration process. Eighteen members of 3,4-
dihydropyrimidine-2-ones were prepared in 20-40% overall yields.  
 
In a conclusion, we have successfully synthesized 3 libraries of heterocycles using 
polymer supported sodium benzenesulfinate as a traceless linker. These examples should 
enlarge the usage of polymer supported sodium benzenesulfinate in solid phase synthesis. 
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1.1 Combinatorial chemistry 
Recent progress in molecular biology and automation has led to an enormous increase in 
efficiency in the search for biologically active compounds. Automated molecular test 
systems enable the determination of biological activity of thousands of new compounds 
in one day. This leads to a rapid depletion of the traditional compound sources and the 
question arises on how the enormous demand for test compounds can be satisfied. Until 
recently biological tests were the bottleneck in the search for new biologically active 
agents. However, today the limiting factor lies in the preparation of compounds in 
sufficient numbers. This is true for the search for new lead structures by random 
screening as well as for the optimization of lead structures. As shown in Figure 1.1, a 
drug discovery process involves both lead discovery and lead optimization steps where 
thousands of compounds would have to be screened. Hence to feed the need for large 
libraries of compounds, the field of combinatorial chemistry was initiated.  
 
Figure 1.1 Key steps in a drug discovery process and the impact of combinatorial 
chemistry 
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This technique, with its power to generate huge numbers of new compounds, is currently 
changing the face of drug discovery. 
 
Combinatorial chemistry encompasses a broad range of chemical techniques which allow 
chemists to generate and test a large number of molecules in a very short time. Figure 1.2 
shows the difference between traditional synthesis and combinatorial synthesis. In 
traditional synthesis, individual molecules are sequentially synthesized. For example, 
compound A would be reacted with compound B to give compound AB, which in turn 
would be isolated and purified. In contrast to this approach, combinatorial chemistry 
offers the opportunity to concurrently synthesize every combination of compounds A1 to 
A9 with compounds B1 to B13, thus providing compounds AiBj (where i=1-9, j=1-13). 
This collection of compounds is referred to as a combinatorial library. In addition, 
because combinatorial synthesis discards the traditional concepts of organic synthesis that 
all compounds and intermediates need to be fully purified and characterized, 
combinatorial synthesis is much faster and more productive than traditional synthesis.   
 
Figure 1.2 Difference between conventional synthesis and combinatorial synthesis 
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Generally, two different strategies are used in combinatorial synthesis: mix-split 
synthesis and spatially separate synthesis.  
1.   Mix-split synthesis was introduced by Furka in 19911. Figure 1.3 shows a simple 
example of a preparation of a small library using this methodology. The starting 
resins are split into 3 portions and reacted with the first set of reagents (A1-A3). 
After the reaction, the resulting resins are mixed thoroughly and the mixture is split 
into 5 portions, each consisting of 3 compounds. After the reaction with the second 
set of reagents (B1-B5), a library of 15 different compounds is obtained. The 
resulting resins are mixed thoroughly and the mixture is split into 4 portions, each 
consisting of 15 compounds. After the reaction with the third set of reagents (C1-C4), 
a library of 60 different compounds is obtained. The primary advantage of this 
method is that very large assemblies of compounds can be synthesized by virtue of 
an exponential growth of compound number with synthetic reaction steps. Since the 
resulting compounds of this method are mixture, methods have to be developed for 
identifying the biologically active components from the mixture. Three approaches 
are generally used for the structural deconvolution of bioactive compounds from 
assay data: iterative deconvolution2, position scanning deconvolution method3 and 
tagging4. 
 
2.     Spatially separate synthesis is the strategy whereby sets of discrete compounds are 
prepared simultaneously in arrays of physically separate reaction vessels or 
microcompartment without interchange of intermediates during the assembly 
process 5. The advantage of this method is that it removes some of the ambiguities 
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associated with pooling compounds. In addition, analytical evaluation of the 
chemical integrity of the compounds is straightforward. The primary disadvantage 




Figure 1.3 Mix-split syntheses 
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Combinatorial synthesis can be carried in solution (solution phase) or on solid support 
(solid or liquid phase). There are four striking advantages of solid phase chemistry over 
solution phase chemistry: 
1.     High yield reaction can be reached on solid support as excess reagent can be used to 
drive the reaction to completion. 
2. Separation and purification are simplified. For each step of a multiple-step synthesis, 
the only purification needed is a resin-washing step. Only the final product obtained 
after cleavage from the solid support needs to be purified. 
3. Automatic synthesis can be easily realized. Adding reagents, filtering and washing 
the resin comprise all the operations in reactions on the solid phase. These simple 
steps allow many simple automated procedures to be developed. 
4. More environmental friendly as toxic compounds bound on the solid support can be 
handled easily without risk to the users or the environment. 
 
The disadvantages of solid phase synthesis are: 
1. Wastage of chemicals and solvents. In each reaction step, excess reagents are 
needed to drive the heterogeneous reaction and a large amount of solvents is needed 
for washing the resins. 
2. Effects of the support on the reaction need to be considered. This includes: more 
factors need to be considered when using solid phase chemistry. These include: i) 
interactions with the support itself must be avoided; ii) a good resin swelling 
solvent is needed; iii) extremely low and high temperature conditions are 
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discouraged; iv) concentrated reagent solutions are required to enhance coupling 
with the support and v) heterogeneous catalyst cannot be used. 
3. Two extra steps must be employed in the synthetic protocol: coupling the starting 
material onto the solid phase and cleavage of the product from the solid phase. 
4. Reactions on solid phase cannot be monitored by simple and effective methods, 
such as TLC. Intermediates and final products can only be monitored by 
sophisticated on-bead methods or after cleavage of the product. 
 
1.2   Solid phase synthesis 
Solid phase synthesis is commonly used for the preparation of combinatorial libraries. 
The synthesis of combinatorial libraries commonly employs solid phase chemistry as it 
offers the opportunity to use filtration as a separation technique to purify both 
intermediate and final compounds. This technique is based extensively on the 
methodology used in solid phase peptide synthesis which was pioneered by Bruce   
Merrifield 6 and for which he was awarded the Nobel Prize in 1984. However today, the 
solid phase techniques have been greatly refined and have been applied to other 
oligomeric molecules, such as peptoids7, oligocarbamates8, oilgoureas9, 
oligonucleotides10 and oligosaccharides11. This shift in focus from peptide to non-peptide 
libraries is attributed to: i) the character of the peptide backbone limits the structural 
diversity of peptides; ii) peptides have poor oral bioavailability and resistance to protease 
degradation; and iii) non-peptide compounds are structurally and chemically diverse and 
some have been shown to possess interesting bioactivities.  
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In solid phase synthesis, (Figure 1.4) starting material A is covalently bound to a 
polymeric support via a linker molecule. The support most frequently used consists of 
crosslinked polystyrene in the form of small beads (diameter about 100 mm), which is 




Figure 1.4 Solid phase synthesis 
 
Solid phase bound A is reacted with another – dissolved – reagent B under appropriate 
conditions. Subsequent reactions are carried out in an analogous manner. In this way the 
molecule to be synthesized is assembled step by step on the polymeric support. After the 
synthesis the product is liberated, i.e. cleaved off the support. The exact conditions under 
which this is done depend on the structure of the linker. The product is then available for 
testing in biological assays 
 
1.3    Solid support 
Solid support is a cross-linked, insoluble, polymeric material that is inert to the 
conditions of synthesis. The most common support is polystyrene cross-linked with 2% 
divinylbenzene (DVB), which was introduced for solid phase peptide synthesis by 
Merrifield6. The physicochemical properties of this gel-like material depended heavily on 
 7
the degree of cross-linking on the polystyrene. A 1-2% DVB cross-linked resin has been 
proven to be optimized between good swelling property (low cross-linking) and 
mechanical stability (high cross-linking).  
 
1.4.   Linkers 
A vital component in any solid phase synthesis strategy is the linker group. It can be 
described as a bifunctional protecting group that tethers the compounds being synthesized 
to the solid support. Many of the earliest linkers used for peptide synthesis are still in 
regular use, but with the divergence to solid phase organic synthesis, advances in the 
design and subtlety of linkers have also progressed in parallel. Hence, the aims of good 
linker design remains unchanged and an ideal linker should fulfill a number of important 
criteria 12: 
1.      It should be cheap and readily available; 
2.     The attachment of the starting material should be readily achieved with high yields; 
3.     The linker needs to be robust - that is it must not be affected by the chemistry used 
to modify and extend the attached compound;  
4.   Cleavage should be achieved under conditions that do not damage the final     
products and the cleavage method used should be easily worked up in large quantity 
and should not introduce impurities that are difficult to remove. 
 
The new wave of interest in solid-phase chemistry focusing on the synthesis of drug-like 
molecules found limitations in the use of conventional linkers, which were designed for 
the synthesis of peptides. Invariably, the linkage to polymer was done at the carboxylic 
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acid, or “C-Terminus”, of the peptide. Functional groups have a dramatic outcome on the 
potential medicinal efficacy of the final drug-like target molecules. With this in mind, the 
solid-phase chemists set about designing new linkers that were termed “traceless linkers”, 
where the point of attachment is not apparent in the final molecule( Figure 1.5). Here we 




Figure 1.5 Traceless cleavage 
 
 























Scheme 1.1 The silicon traceless linker by Ellman 
 
The design of this type of linker is based on the well-known protodisilylation of the Si-Ar 
bond. Ellman was one of the pioneers in this field13. He developed a silicon-based 
traceless linker and used it in the synthesis of 1,4-benzodiazepine derivatives (Scheme 
1.1). The synthesis of the silicon linker involves a lithium-halogen exchange and, after 
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chlorosilane attachment, subsequent coupling with an aryl halides. In addition, cleavage 
of these linkers can be accomplished by electrophiles other than protons to yield 
halogenated residues. The silicon linker, which is now commercially available, has been 
improved by various other groups14. 
 
1.4.2. Germanium linkers 
 
Germanium, an element with similar properties to silicon, has also been used in traceless 
linkers chiefly by Ellman15. The germanium linker is very similar to the silicon linker and 
the chemistry performed to synthesize 1,4-benzodiazepines was identical. Conventional 




































Scheme 1.2 Synthesis of a benzodiazepine library with the use of a germanium traceless 
linker by Ellman: a) R1COCl, [Pd2(dba)3], K2CO3, iPr2EtN, THF; b) 2-
Chlorobenzo[1,2,3]dioxaborole, iPr2EtN, CH2Cl2; c) 1.R2CH(NHFmoc)COF, 2. 





1.4.3. Sulfur linkers 
 
Recently, Janda et al. reported the use of sulfones as suitable anchoring groups for 
alkanes in soluble polymer chemistry16. After oxidation of a sulfide to a sulfone, 
treatment of these sulpones with sodium/mercury gives rise to the formation of the parent 
hydrocarbon in high yields.(Scheme 1.3) However, aqueous work-up is necessary to 
















Scheme 1.3 The sulfone traceless linker for alkanes: a) 5% Na/Hg, Na2HPO4, MeOH, -
400C→00C, 96%. 
 
1.4.4. Selenium linkers 
 
Selenium has proved to be a useful element for traceless solid-phase synthesis, attracting 
much recent interest. The selenium-carbon bond is prone, owing to its weakness, to 
undergo homolytic cleavage to give radicals. This fact was first recognized and used for 
solid-phase synthesis by Heitz et al. in 197617a. Recently Nicolaou17b et al. and 
Ruhland17c et al. have independently developed more efficient methods for the 
preparation of selenium-containing supports in their development of traceless linkers. 
Starting from polystyrene, various steps, including selenation with selenium powder or 
MeSeSeMe, give rise to the formation of selenium resins, which may be alkylated to give 
selenoethers. The traceless cleavage yielding alkanes can be conducted by reduction with 
tributyltinhydride, while the formation of alkenes can be observed after mild oxidation 
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(Scheme 1.4). This linker holds promise for wide applications, since the starting 
materials are conveniently available, although toxicity of reagents and starting materials 

















Scheme 1.4 The selenium traceless linker for alkanes and arenas: a) THF, 230C, 12h; b) 2 
equiv. of Bu3SnH, AIBN (0.5 mol%), PhMe, reflux, 6h, 89%(2steps); c) 1 equiv of H2O2 
(30%), THF, 230C, 12h, 78% (2steps). 
 
1.4.5. Nitrogen linkers 
The use of nitrogen as the element of linkage in traceless linkers has been centered 
around the chemistry of diazonium compounds. Brase and Enders18 introduced a triazene 
linker, later to be named the T1-triazene traceless linker (Scheme 1.5). 
 
The benzylamine resin was synthesized in one step from Merrifield resin. Diazonium 
salts were coupled to the resin to give the triazene , which was used in a Heck coupling 
reaction to give the resin bound product. The cleavage was facilitated with either HCl in 
THF or reductive deamination using H3PO2 in dichloroacetic acid to give the Heck 
coupling product in 81% yield. Other reactions were performed after the Heck reaction 
on different substrates, including Sharpless dihydroxylation and Diels-Alder, in good 






















Scheme 1.5 The nitrogen traceless linker by Brase and Enders 
 
 
1.4.6. Phosphorus linkers 
It is well known that the phosphorus-carbon bond in phosphonium salts is readily 
cleavable as demonstrated in their use as Wittig salts. However, this bond can also be 
cleaved by the aid of a base in absence of an aldehyde. Hence, the polymer-bound 
phasphonium salt gives a direct access to methylarenes (Scheme 1.6). An interesting 
feature of this linker is the fact that carbonyl compounds can be olefinated and this leads 















Scheme 1.6 The phosphorus traceless linker for methylarenes  
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1.4.7. Boron linkers 
A novel boronate linker20 (Scheme 1.7) was developed from resin bound alcohol, which 






















Scheme 1.7 Boron traceless linker by Pourbaix et al.20
 
The functional group X was then derivatized in a number of ways including ester and 
amide formation, reductive amination, and a Ugi four-component condensation, giving 
derivatized boronate. A mild protodeboronation cleavage protocol was developed using 
silver diamine nitrate in water and THF to release the functionalized aromatic compound, 
regenerating the initial linker. The processes that were performed using this linker gave 
>45% overall yield and>80% product purity, although the chemistry was somewhat 
limited. 
  
1.4.8. Chromium linkers 
 
A traceless synthesis protocol has been developed 21 using chromium carbonyl complexes 



















Scheme 1.8 The chromium traceless linker by Gilboson et al21. 
 
Chromium carbonyl complex was photochemically loaded onto polystyrene phosphine 
resin to give resin-bound complex. Reduction of the ketone gave the alcohol, with 
cleavage facilitated by heating in pyridine to release the alcohol. The yields for the 
individual steps were calculated using 31P NMR. The reduction proceeded in 62% yield 
and the cleavage in 90% yield. Rigby also reported a similar traceless δ-arene chromium 
linker for the synthesis of tertiary alcohols and esters22. 
 
1.4.9. Tin linker 
 
Tin hydride reagents are versatile tools for the functionalization of alkenes and alkynes. 
Based on this concept, Nicolaou23 and co-workers have developed a polymer-bound tin 
hydride, which reacts under hydrostannylation condition with alkynes to give 
alkenylstannanes, (Scheme 1.9). The latter undergo, after further transformation, 
proteolytic traceless cleavage, to yield unsubstituted alkenes. Moreover, the stannane can 
be employed as a starting material for an intramolecular Still reaction to produce larger 























Scheme 1.9 The tin traceless linker for alkenes: a) 1. 3-butynol, AIBN, 1100C;  2. glutar 
anhydride, DMAP; 3. DCC, DMAP, (2-iodophenyl)-methanol; b) [Pd(PPh3)4], toluene, 
1000C, 51%; c) H+  
 
 
1.5 Analytical methods in combinatorial chemistry 
 
Structure elucidation based on the small amounts of material on each bead (an as large as 
possible part of which is supposed to be used for the biological test) represents a veritable 
challenge to analytical chemistry. To enable one to cope with the huge number of 
compounds produced by the split and combine method, the possibility of automation and 
parallelization is also a requirement.  
 
To solve this problem, apart from indirect methods which will not be discussed here, 
mass spectroscopy is the technique of choice despite recent progress in IR- 24 and NMR-
spectroscopy 25, 26. The first reports on the use of mass spectroscopy in the context of 
combinatorial chemistry describe work done on peptides 27–30. With the growing interest 
in solid phase synthesis of small organic molecules these methods were applied to 
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nonpeptidic compounds as well 31.The cleavage from the polymeric support was achieved 
by incubation with TFA (vapor) or photochemically 28. It was also possible to perform 
the cleavage reaction in the mass spectrometer itself under MALDI-TOF conditions 29. In 
addition, if isotopically labeled materials are used, 1H and 13C NMR spectra can be 
obtained from a single resin bead 26. 
 
 
Figure 1.6 Monitoring by IR spectroscopy of β-ketoester formation on solid phase32. 
 
IR-spectroscopy 24 has proven very useful as a routine tool and is employed in solid 
phase synthesis the same way as thin layer chromatography is commonly used in 
classical solution synthesis. As shown in Figure 1.6 the formation of a β-ketoester on 
solid phase can be monitored readily32. IR microscopes could even allow the use of single 
resin beads for analysis. 
 
The reliable characterization of compound mixtures, which were obtained through a split 
and combine synthesis, is another problem which is encountered with increasing 
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frequency. This is similar to the situation when one is confronted with having to elucidate 
the structure of a biologically active component in microbial broths and the like. An 
important difference, however, is that – if the synthesis was successful – all components 
are present in equimolar concentrations and it is also known which structures were 
synthesized. Meutermans et al.33 were able to show by ion spray MS that mixtures of di- 
and tetrahydroisoquinolines synthesized on solid phase did indeed contain all expected 
compounds. 
 
Figure 1.7 HPLC-MS analysis of an equimolar mixture of 16 heterocyclic compounds 
generated by a split and combine synthesis32. 
 
For mixtures of low complexity HPLC/MS-coupling has been found to be very useful. 
Figure 1.7 shows the HPLC-trace of a sublibrary containing 16 different heterocyclic 
compounds (4 possibilities each for substituents A and B, C is kept constant). Further 
analysis with FAB-MS confirmed the presence of all expected molecular structures and 
assigned each of them unambiguously to a peak in the chromatogram32. 
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MS-methods have also been used to advantage in the characterization of very complex 
mixtures. While early reports describe only applications in the peptide field30, complex 
combinatorial mixtures of small organic molecules have also been characterized. Rebek, 
Jr. et al.34 applied several MS-methods in combination to investigate how many of the 
theoretically possible products of their library synthesis had actually been formed. 
 
In future, analytical chemistry will certainly have to live up to further challenges as 
combinatorial chemistry continues to be develop further and new applications e.g. in 
materials sciences35 or catalyst development36 become a reality. 
 
1.6 Sulfone chemistry 
The sulfone functional group (1-1) owes its name to its formal resemblance to the 
carbonyl group and is best represent as the resonance between two canonical forms (1-2). 
This group is associated with a high degree of thermodynamic stability. It can also 
function as a proton acceptor, i.e. it possesses essentially basic properties. Three 
important properties of the sulfonyl group mainly determine the overall properties of 












Figure 1.8 The structure of sulfone 
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nonenolisablity of the sulfonyl group, its elecron attracting (-I) effect, and the resultant 
negative charge on the oxygen atoms. The sulfone group renders acidic the hydrogen 
atoms attached to the α-carbon atoms. So sulfonyl group plays an important role in both 
organic synthetic and pharmaceutical aspects37.  
 
The sulfone containing heterocycles have been shown to possess diversified bioactivities. 
Many organic sulfones have shown antibacterial, antimalarial, antihelmintic, antilepral, 
antineoplastic, anti-inflammatory and antidiabetic acitivities38. As shown in Figure 1.9, 
compound 1-3 exhibited anticoccidial activity in chicken (Eimeria tenella) with an MIC 









Figure 1.9 One example of organic sulfonyl compounds 
 
The use of sulfones, acting as an auxiliary group, is an important synthetic strategy, 
especially for making carbon-carbon double bonds. This functional group can modify the 
polarity of the molecule by acting as an electron-withdrawing group to stabilize 
carbanions or as a leaving group. Due to this dual chemical behavior, sulfones have been 
called chemical chameleons. Nowadays there are several synthetic methodologies in 
which sulfones are involved as activating groups. In the last 30 years the use of sulfones 
as intermediates in total synthesis of many natural products has become a classic. After 
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the required synthetic operation, the sulfone moiety can be exchanged by hydrogen 
(reductive desulfonation), an alkyl group (alkylative desulfonation), a carbonyl 
functionality (oxidative desulfonation) or a nucleophile (neucleophilic displacement) as 
well as α, β-elimination or a sulfur dioxide excursion process39. An example of the 
application of sulfone chemistry in total synthesis is described in Scheme 1.1040. 
Heliannuol A, 1-10, was isolated from the extracts of cultivated sunflowers. It is believed 
to be involved in the allelopathic action of sunflowers. Starting with sodium 
benzenesulfinate, unsaturated sulfone 1-5 was obtained. After hydogenation of 1-5, 
double bond was reduced and the benzyl protecting group was removed to afford 1-6. 
After incorporation of the desired ester group, ring closure reaction was accomplished by 
treatment 1-7 with lithium bis(trimethylsilyl) amide (LiHMDS). After reduction of the 
carbonyl group, compound 1-9 was obtained, which afforded Heliannuol A, 1-10, by 






























Scheme 1.10 An example of the application of sulfone in total synthesis. 
1.7 Our purpose. 
 Due to the importance of solid supports and linkers in solid phase synthesis, it is 
important for chemists to develop more suitable solid supports and linkers to transfer 
solution reactions onto solid supports. The linker we are interested in is the polymer 
supported sodium benzenesulfinate. Sodium benzenesulfinate is used widely to form 
sulfones in solution phase organic synthesis. Sulfone chemistry plays an important role in 
organic chemistry, and many desulfonation methods are available.  Hence polymer bound 
sodium benzenesulfinate can be used as a linker in solid phase synthesis. Although such 
resin was used in solid phase synthesis back in 1970s41, the applications of polymer 
supported sodium benzenesulfinate in solid phase library synthesis have only been 
reported by two other research groups besides ours.      
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 M. J. Kurth et al. Tetrahedron Lett., 1997, 44, 7709-7712





Figure 1.11 Kurth and his coworker’s application of polymer supported sulfinate 
 
The first report on using polymer supported sulfinate as solid support to synthesize small 
molecular libraries was reported by Huang and his coworkers42. With this solid support 
they had initially prepared 4,5-substituted-1,2,3-triazoles and 2,5-substituted-1,3,4-
oxadiazoles43 (Figure 1.10). More recently, in 2001, the same group reported the 
synthesis of a small library of hydatoins and urea derivatives using the same linker44 
(Figure 1.10).  
   
In 1997, Kurth and coworker published their first paper on the preparation of 
trisubstituted olefins (Figure 1.11) with polymer supported sulfinate resin45. Two years 
later, they published the use of the same linker for the preparation of the library of 
cyclobutylidenes46 (Figure 1.11). This was followed by the synthesis of the libraries of 
4,5,6,7-tetrahydrisoindole derivatives47, isoxazolocyclobutanones, 
isoxazolinocyclobutenones48, enones49 and 3,5-disubstituted cyclopet-2-enones50 in the 
recent two years (Figure 1.11). Our group has also made various contributions to the 
development of this linker. In 2001-2004, we made a series of nitrogen-containing 
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Figure 1.12 Lam and his coworker’s application of polymer supported sulfinate 
 
But compared to sodium benzenesulfinate, applications of polymer supported sulfinate 
resin are still limited and largely unexplored. One of the purposes of this study is thus to 
widen the use of polymer supported sodium benzenesulfinate in solid phase synthesis. As 
heterocyclic compounds have been demonstrated to have various biologically interesting 
properties, we decided to examine the solid phase synthesis of this class of compounds 


































































2.1.1 Importance of pyridones 
 
Pyridones represent a unique class of pharmacophore which are observed in various 
therapeutic agents52 and antibiotics.53 They are also versatile precursors for the 
construction of complex natural products,54 pyridines55 and larger pyridone systems 
(Figure 2.1) such as those found in the nitroguanidine insecticide Imidacloprid56 and 
subtype selective GABAA receptor agonists.57    
 
Figure 2.1 Structures with strong anti bacterial effect. 
 
 
2.1.2 Solution phase synthesis of 2-pyridones 
Methodologies for the preparation of pyridones have attracted much attention from both 
industry and academia, and various solution-phase syntheses of these compound have 
been reported.58-59 They have been prepared by numerous methods, e.g. oxidation of an 
N-substituted pyridinium salt and Knovenagel-type reactions, such as cross-condensation 
of cyanoacetoamide and dicarbonyl compounds with basic catalysts or by the reaction of 
2-pyrones with amides.58-59 Despite this large number of existing methods for their 
synthesis, new procedures are continuously being developed. Scheme 2.1 shows an 
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Scheme 2.1 Example of a solution phase synthesis of 2-pyridones. 
 
2.1.3 Solid phase synthesis of pyridones 
In recent years, synthetic methods (Scheme 2.2) for the preparation of 2- and 4-pyridones 
on solid-phase have also been examined.60 To the best of our knowledge, only one of 
these reports (Scheme 2.3) concerns the traceless preparation of these compounds. In this 
report, 4-pyridones were prepared through condensation of resin-bound acylpyridiniums 
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Chen, C.; Munoz, B. Tetrahedron Lett. 1998, 39, 6781-6784. 
Scheme 2.3 Traceless synthesis of 4-pyridones 
 
2.1.4 Our purpose 
In order to realize the traceless solid phase synthesis, we herein report the application of 
2-1 for the convenient traceless synthesis of 2-pyridones. The key steps in our synthesis 
include (i) sulfinate S-alkylation, (ii) sulfone anion alkylation with an epoxide, (iii) γ-
hydroxyl sulfone  γ-ketosulfone oxidation, and (iv) traceless product release by a one-
pot elimination-cyclization process (Scheme 2.4).  
 
Scheme 2.4 Synthesis of 2-pyridones using sodium benzenesulfinate as a traceless linker 
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2.2 Results and discussion 
Polystyrene/1% divinylbenzene sodium benzenesulfinate (2-1) in NBu4I/KI/DMF was 
reacted with an alkyl or aryl bromide at room temperature. The formation of 2-2 was 
easily monitored by IR spectroscopy for the appearance of the sulfone stretches (2-2: 
νasym 1313.5 cm-1 and νsym 1150.4 cm-1). Alkylation of 2-2 with an alkyl or aryl epoxide 
gave 2-3 which could not be reliably analyzed by IR spectroscopy. Hence we proceeded 
to oxidize 2-3 with the Jones’ reagent to give resin 2-4. This transformation was 
monitored by IR spectroscopy for the appearance of the carbonyl stretch (2-4: νmax 
1687.7 cm-1). Treatment of 2-4 with potassium tert-butoxide/DMSO and 2-
cyanoacetamide in air at 50oC gave 3-cyano-2-pyridones in 28-48% overall yields. 
Similarly, reactions with malonamide or methyl malonate monoamide gave pyridine-3-
carboxylic acids and pyridine-3-carboxylic acid amides in 20-49% (Table 2.1) overall 
yields. However in the cases of 2-4f and 2-4k, where R1 and R2 are both alkyl groups, it 
was observed that reactions at 50oC gave the intermediates, 6-hydroxy-6-methyl-2-oxo-4-
propyl-piperidine-3-carbonitrile and 6-hydroxy-6-methyl-2-oxo-4-propyl-piperidine-3-
carboxylic acid, respectively. Aromatization was achieved only when the reaction 
mixtures were heated at 70oC.  It was noted that for combinations where R2 is an alkyl 
group, the corresponding 2-pyridones were obtained in lower yields. This would be 
expected as the protons on these methyl groups are acidic and could readily be removed 
under basic conditions to generate enolates which, in turn, could undergo side-reactions. 
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To provide an additional diversity in this library, we carried out the elimination-
cyclization process under nitrogen. Decyanative aromatization due to “oxygen 






Entry X R1 R2 % Yielda
2-5a CN Ph Ph 43 
2-5b CN p-BrPh Ph 45 
2-5c CN p-MeOPh Ph 48 
2-5d CN Ph Me 29 
2-5e CN p-MeOPh Me 28 
2-5f CN CH3CH2CH2 Me 14b
2-5g COOH Ph Ph 46 
2-5h COOH Ph Me 20 
2-5i COOH CH3CH2CH2 Me 12b
2-5j CONH2 Ph Ph 49 
2-5k CONH2 Ph Me 26 
2-5l H Ph Ph 49 
2-5m H p-BrPh Ph 44c
2-5n H Ph Me 28 
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2-5o H p-BrPh Me 25 
a Purified yield calculated based on original loading of the resin. Purities were >97% as 
evaluated by NMR.  
b  Yield obtained after further purification by flash chromatography. 
Table 2.1 Solid phase synthesis of 3,4,6-trisubstituted-2-pyridones 
 
2.3 Conclusion 
We have demonstrated a general protocol for the regiospecific solid-phase synthesis of 
3,4,6-trisubstituted-2-pyridone derivatives using polystyrene/1% divinylbenzene sodium 
sulfinate as a traceless linker. Product 2-5 precipitated from water under acidic conditions 
and could be expediently purified without the need for column chromatography. Since a 
variety of reagents can be used in steps (i), (ii) and (iv), the overall strategy is applicable 
for library generation. 
 
2.4 Experimental section 
2.4.1 General procedures  
All experiments involving moisture or air sensitive were perfomed under N2 in flame-
dried glassware capped with a rubber septum. Solid-phase reactions were agitated using a 
Flask shaker SF1 (Stuart Scientific). 
 
2.4.2 Materials 
Analytical grade chemical reagents were purchased from commercial suppliers (Aldrich, 
Fluka, Merck, TCI). The sodium benzenesulfinate resin was purchased from Hecheng Co. 
of Nankai University. All of these compounds were used without further purification. 
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Technical ethyl acetate and hexane were distilled before used. Other solvents are 
analytical grade and were used for washing and purification. 
 
2.4.3 Chromatography 
Analytical thin layer chromatography was performed using Merck Kieselgel 60 F254 pre-
coated silica gel glass plate. Visualization of the compounds on the silica gel glass plate 
was carried out by UV illumination and staining with iodine vapor, ninhydrin solution or 
phosphomolybdic acid hydrate solution. Flash column chromatograph was performed 
with silica (Merck, 70-230 mesh) under pressure. 
 
2.4.4 Physical data 
1H NMR and 13CNMR spectra were measured at 298K on Bruker DPX 300 Fourier 
Transform spectrometer. Chemical shifts were reported in δ (ppm), relative to the internal 
standard of tetramethylsilane (TMS). And the signals observed were described as: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). The number of 
protons (n) for a given resonance was indicated as nH. All Infra-red (IR) spectra were 
recorded on a Bio-Rad FTS 165 spectrometer. Mass spectrometry was performed on a 
VG Micromass 7035 spectrometer under electron impact (EI). Crystallography data were 
collected at room temperature using a Siemens R3m/V diffractometer with Mo-Kα 
radiation (λ = 0.71060 Å). Lorentz and polarization corrections, structure solution by 
direct methods, full-matrix least-squares refinements and preparation of figures were all 
performed by the SHELXTL-Plus PC program package. All non-hydrogen atoms were 
refined anisotropically whereas hydrogen atoms were placed at calculated positions with 
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isotropic displacement coefficient being assigned a value that is 1.6 times that of the atom 
to which it is attached.  
 
2.4.5 Typical experimental procedure  
Resin 2-1 (1g, 2.1 mmol/g, 100-200 mesh) was swollen under nitrogen in 20 ml DMF for 
30 min. Alkyl or aryl bromide (5 equiv.), KI (5 equiv.) and tetrabutylammonium iodide 
(1 equiv.) were added and the mixture was shaken at room temperature for 24 h. The 
resin was then filtered and washed sequentially with DMF (20 ml x 2), H2O (20 ml x 2), 
ethanol (20 ml x 2), CH2Cl2 (20 ml x 2) and diethyl ether (20 ml  x 2), and dried 
overnight in a vacuum oven at 40oC to afford resin 2-2. 
 
BuLi (5 equiv.) was added to DMSO (10 equiv.) in THF (10mL) at 0°C and stirred for 5 
min. The resulting dimsyl anion solution was transferred to a suspension of resin 3-14 
(0.3g) in THF (8mL) at room temperature and the mixture was shaken for 1 hour. The 
epoxide (8 equiv.) was added and the mixture was shaken for a further 12 hours. After 
which, the reaction was quenched with 10%HCl (aq.) and filtered. The resin obtained was 
washed sequentially with DMF (20mL*2), H2O (20mL*2), EtOH (20mL*2), DCM 
(20mL*2) and ether (20mL*2), and dried overnight in a vacuum oven at 40°C to afford 
resin 2-3. 
 
Jones’ reagent (10 equiv.) was added to a suspension of resin 2-3 (0.3g) in acetone (8mL) 
at 0°C and the mixture was stirred for 12 hours. The mixture was filtered and the resin 
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washed sequentially with H2O (20mL*2), DCM (20mL*2) and ether (20mL*2), and 
dried overnight in a vacuum oven at 40°C to afford resin 2-4 as light green colored beads. 
Resin 2-4 (1 g) was swollen in 20 ml DMSO for 1 h. t-BuOK (9 equiv.) and the amide 
(12 equiv.) were added and the resulting mixture was heated at 50oC in air for a further 8 
h. After which the resin was filtered and washed with DMF (5 ml x 2) and H2O (5 ml x 2). 
The combined washings was diluted with H2O (80 ml) and 2M HCl was added until pH 2 
was achieved. The precipitate formed was filtered, washed with water and dried under 






2-Oxo-4,6-diphenyl-1,2-dihydro-pyridine-3-carbonitrile 2-5 a: 1H (DMSO-d6): 12.8 
(1H, br, NH), 7.89 (2H, m, ArH), 7.73 (2H, m, ArH), 7.56 (6H, m, ArH), 6.84 (1H, s, 
CH).13C (DMSO-d6): 161.9, 159.7, 135.3, 131.1, 130.3, 128.8, 128.7, 128.2, 127.7, 116.4, 






4-(4-Bromo-phenyl)-2-oxo-6-phenyl-1,2-dihydro-pyridine-3-carbonitrile 2-5b: 1H 
NMR (300 MHz, DMSO-d6): δ 6.83 (s, 1H, CH), 7.53 (m, 3H, ArH), 7.69 (m, 2H, ArH), 
7.76 (m, 2H, ArH), 7.87 (m, 2H, ArH), 12.60 ( br, 1H, NH). 13C NMR (500 MHz, 
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DMSO-d6): 162.1, 160.9, 131.4, 130.1, 128.6, 127.5, 126.7, 123.7, 116.5, 103.7, 95.4. 






4-(4-Methoxy-phenyl)-2-oxo-6-phenyl-1,2-dihydro-pyridine-3-carbonitrile 2-5c: 1H 
NMR (300 MHz, DMSO-d6): δ 3.85 (s, 3H, OCH3), 6.79 (s, 1H, CH), 7.12 (d, J=8.7 Hz, 
2H, MeOArH), 7.55 (m, 3H, ArH), 7.74 (d, J=8.7 Hz, 2H, MeOArH), 7.90 (m, 2H, ArH), 
12.70 (br, 1H, NH). 13C NMR (500 MHz, DMSO-d6): 162.2, 161.1, 159.2, 151.0, 132.3, 
131.1, 129.9, 128.9, 127.7, 116.8, 114.2, 105.9, 97.5, 55.4. HRMS (EI): Calcd for 






6-Methyl-2-oxo-4-phenyl-1,2-dihydro-pyridine-3-carbonitrile 2-5d: 1H NMR (300 
MHz, DMSO-d6): δ 2.31 (s, 3H, CH3), 6.33 (s, 1H, CH), 7.55 (m, 5H, ArH), 12.5 (br, 1H, 
NH). 13C NMR (500 MHz, DMSO-d6): 161.4, 160.1, 152.2, 136.1, 130.3, 128.8, 127.9, 






4-(4-Methoxy-phenyl)-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile 2-5e: 1H 
(DMSO-d6): 12.7 (1H, br, NH), 7.90 (2H, m, ArH), 7.74 (2H, d, J=8.7, MeOPhH), 7.55 
(3H, m, ArH), 7.12 (2H, d, J=8.7, MeOPhH), 6.79 (1H, s, CH), 3.85 (3H, s, CH3). 13C 
(DMSO-d6): 162.2, 161.1, 159.2, 151.0, 132.3, 131.1, 129.9, 128.9, 127.7, 116.8, 114.2, 





6-Methyl-2-oxo-4-propyl-1,2-dihydro-pyridine-3-carbonitrile 2-5f: 1H NMR (300 
MHz, CDCl3): δ 0.98 (t, J=7.3 Hz, 3H, CH3), 1.68 (m, 2H, CH2), 2.39 (s, 3H, CH3), 3.11 
(m, 2H, CH2), 6.27 (s, 1H, CH), 13.1 (br s, 1H, NH). 13C NMR (500 MHz, CDCl3): 160.7, 
160.5, 152.1, 135.9, 106.8, 97.6, 36.9, 24.1, 19.4, 14.8. HRMS (EI): Calcd for C10H12N2O 






2-Oxo-4,6-diphenyl-1,2-dihydro-pyridine-3-carboxylic acid 2-5g: 1H NMR (300 MHz, 
DMSO-d6): δ 6.71 (s, 1H, CH), 7.46 (m, 8H, ArH), 7.87 (m, 2H, ArH), 12.99 (br, 1H, 
COOH). 13C NMR (500 MHz, DMSO-d6): 166.5, 162.5, 153.0, 148.1, 138.4, 132.9, 
130.4, 128.9, 128.3, 127.6, 127.4, 118.3, 107.9. HRMS (EI): Calcd for C18H13NO3 









6-Methyl-2-oxo-4-phenyl-1,2-dihydro-pyridine-3-carboxylic acid 2-5h: 1H NMR (300 
MHz, DMSO-d6): δ 1.89 (s, 3H, CH3), 6.41 (s, 1H, CH), 7.45 (m, 3H, ArH), 7.65 (m, 2H, 
ArH), 12.78 (br, 1H, COOH). 13C NMR (500 MHz, DMSO-d6): 164.1, 163.1, 161.2, 
136.9, 136.5, 126.7, 126.5, 126.1, 117.4, 103.9, 21.2. HRMS (EI): Calcd for C13H11NO3 






6-Methyl-2-oxo-4-propyl-1,2-dihydro-pyridine-3-carboxylic acid 2-5i: 1H NMR (300 
MHz, CDCl3): δ 1.05 (t, J=7.3 Hz, 3H, CH3), 1.75 (m, 2H, CH2), 2.29 (s, 3H, CH3), 3.21 
(m, 2H, CH2), 6.92 (s, 1H, CH), 11.28 (br, 1H, NH), 15.13 (br s, 1H, COOH). 13C NMR 
(500 MHz, CDCl3): 166.9, 165.4, 165.1, 138.3, 116.5, 110.5, 37.5, 23.8, 19.5, 14.9. 








2-Oxo-4,6-diphenyl-1,2-dihydro-pyridine-3-carboxylic acid amide 2-5j: 1H NMR 
(300 MHz, DMSO-d6): δ 4.87 (m, 2H, NH2), 6.66 (s, 1H, CH), 7.49 (m, 6H, ArH), 7.73 
(m, 2H, ArH), 7.81 (m, 2H, ArH), 11.95 (br, 1H, NH). ). 13C NMR (500 MHz, DMSO-
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d6): 167.4, 163.7, 161.2, 151.8, 149.6, 138.5, 129.9, 128.8, 128.7, 128.5, 128.2, 127.8, 








6-Methyl-2-oxo-4-phenyl-1,2-dihydro-pyridine-3-carboxylic acid amide 2-5k:  1H 
NMR (300 MHz, DMSO-d6): δ 2.19 (s, 3H, CH3), 4.91 (m, 2H, NH2), 6.50 (s, 1H, CH), 
7.41 (m, 3H, ArH), 7.58 (m, 2H, ArH), 11.83 (br, 1H, NH). 13C NMR (500 MHz, 
DMSO-d6): 167.4, 164.8, 161.1, 137.5, 136.9, 128.7, 128.5, 128.1, 127.9, 104.6, 19.3. 





4,6-Diphenyl-1H-pyridin-2-one 2-5l: 1H (DMSO-d6): 11.8 (1H, br, NH), 7.88 (2H, m, 
ArH), 7.79 (2H, m, ArH), 7.48 (6H, m, ArH), 6.99 (1H, d, J=1.8, CH), 6.67 (1H, d, J=1.8, 
CH). 13C (DMSO-d6): 163.9, 153.5, 148.8, 137.0, 133.9, 130.3, 130.1, 129.3, 129.0, 








4-(4-Bromo-phenyl)-6-phenyl-1H-pyridin-2-one 2-5m: 1H NMR (300 MHz, DMSO-
d6): δ 6.68 (m, 1H, CH), 7.00 (m, 1H, CH), 7.49 (m, 3H, ArH), 7.67 (m, 2H, ArH), 7.70 
(m, 2H, ArH), 7.89 (m, 2H, ArH), 11.7 (br, 1H, NH). 13C NMR (500 MHz, DMSO-d6): 
167.0, 155.4, 148.1, 137.1, 133.3, 131.6, 130.3, 129.9, 127.9, 125.3, 114.6, 107.4. HRMS 






6-Methyl-4-phenyl-1H-pyridin-2-one 2-5n: 1H NMR (300 MHz, DMSO-d6): δ 2.22 (s, 
3H, CH3), 6.34 (m, 1H, CH), 6.37 (m, 1H, CH), 7.47 (m, 3H, ArH), 7.65 (m, 2H, ArH), 
11.6 (br, 1H, NH). 13C NMR (500 MHz, DMSO-d6): 163.3, 151.9, 145.8, 137.5, 129.3, 






4-(4-Bromo-phenyl)-6-methyl-1H-pyridin-2-one 2-5o: 1H NMR (300 MHz, DMSO-d6): 
δ 2.22 (s, 3H, CH3), 6.33 (m, 2H, CH), 7.64 (m, 4H, ArH), 11.6 (br, 1H, NH). 13C NMR 
(500 MHz, DMSO-d6): 163.2, 150.5, 146.0, 136.6, 131.8, 128.7, 122.7, 112.7, 102.7, 





























3.1.1 The importance of imidazoles 
The imidazole moiety, as part of the side chain in histidine, plays a major role in the 
biological functions of many peptides and proteins. Functionalized imidazoles also 
comprise an important class of pharmacologically active compounds (Figure 3.1) with a 
wide range of interesting properties. Members of this class of compounds are known to 
possess NO synthase inhibition,62 antifungal,63 antimycotic,64 antibiotic,65 antiulcerative66 
and CB1 receptor antagonistic activities (Figure 3.2).67 
 
Figure 3.1 Examples of imidazole-containing drugs 
 
Figure 3.2 Examples of imidazoles include p38 inhibitor I and COX-2 inhibitor II 
 
3.1.2 Solution phase synthesis of imidazoles 
Methodologies for the preparation of imidazoles have attracted much attention from both 
industry and academic and numerous solution-phase syntheses of these compounds have 
been reported68, For example, elegant approaches based on van Leusen’s TosMIC 
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chemistry68f have been reported; however, this methodology has not been demonstrated 
to provide direct access to tetrasubstituted imidazoles, and subsequent activation 
substitution is necessary. Other methods of quick access of imidazoles have also been 
developed.  Scheme 3.1 shows one method by Shilcrat, S. C et al68c.This approach begins 
with the synthesis of 2-butyl-1H-imidazole-4-methanol using methyl imidate. Imidazole 
is oxidized and chlorinated to yield 2-butyl-4-chloro-1H-imidazole-5-carboxaldehyde. 
  
 





















Scheme 3.1 One example of solution phase synthesis of imidazole Key: (a) 1,3-
dihydroxyacetone dimer, NH3, 600C; (b) MnO2, CH2Cl2; (c) N-chlorosuccinimide; (d) 
methyl 4-(bromomethyl)benzoate, K2CO3, DMF; (e) H2, Pd/C. 
 
3.1.3 Solid phase synthesis of imidazoles 
In recent years, synthetic methods for the preparation of imidazoles on solid-phase 
(Scheme 3.2) have been examined.69 However only one of these reports concerns the 
construction of 1,2,4,5-tetrasubstituted imidazoles. In this report(Scheme 3.3), 1,2,4,5-
tetrasubstituted imidazoles were prepared via a seven steps traceless synthesis strategy 
based on the benzylic acylammonium chloride reactivity.69c Thus, new methods 
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Scheme 3.3 Traceless synthesis of imidazoles  
 
3.1.4 Our purpose 
A promising alternative approach involves the synthesis of imidazoles through the 
cyclization of α-ketoamides with amines. α-Ketoamides could be achieved through the 
coupling of aldehydes with acylamines and the latter could, in turn, be obtained from 
arylsulfonylamides through the elimination of sulfinic acid.70 To our knowledge, this 
methodology has not been employed for solid-phase imidazole synthesis. We herein 
describe a rapid solid-phase approach to 1,2,4,5-tetrasubstituted imidazoles via 
arylsulfonylamides on resin. Key steps in the synthesis include (i) sulfinate acidification, 
(ii) sulfinic acid condensation with aldehyde and amine, and (iii) traceless product release 
by a one-pot elimination-cyclization reaction (Scheme 3.4). Since a variety of reagents 
can be used in steps (ii) and (iii), the overall strategy appears to be applicable for library 
generation. 
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 Scheme 3.4 Solid phase synthesis of 2,4,5-trisubstituted-1,3-azoles 
 
3.2 Results and discussion 
3.2.1 Solution phase synthesis of imidazoles.  
Prior to the solid phase synthesis, preliminary solution-phase studies were carried out to 
survey the requisite reaction conditions and establish the modifications for the solid-
phase synthesis. To begin our investigation, N-(benzenesulfonylphenylmethyl)benzamide 
(3-10) was prepared by treating sodium benzenesulfinate with HCl in water at room 
temperature to give benzenesulfinic acid (3-9) in 93% yield (Scheme 3.5).71 Subsequent 
condensation of 3-9, benzaldehyde and benzamide according to a procedure from Sisko 
and co-workers72 provided 3-10 in 87% yield. Coupling of 3-10 with pyridine-4-
carbaldehyde in the presence of triethylamine and 20 mol% thiazolium catalyst gave the 
α-ketoamide, N-(2-oxo-1-phenyl-2-pyridin-4-yl-ethyl)benzamide (3-11), in good yield 
(92%).9 Attempts to cyclize 3-11 with NH4OAc/EtOH in air did not provide the 
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imidazole 3-5a and 3-11 was recovered. However, when the reaction was proceeded 
under nitrogen condition, 3-5a was formed in 85% yield. 
 
Scheme 3.5 Solution phase study 
 
3.2.2 Solid phase synthesis of imidazoles, oxazoles and thiazoles.  
With the solution-phase pathway established, we proceeded to develop the solid-phase 
route to these compounds. Due to the poor swelling ability of the resin in water, a DMF-
H2O (v/v:1:3) mixture was used as the solvent for the preparation of 3-2. Polystyrene/1% 
divinylbenzene sodium sulfinate (3-1, 100-200 mesh) in DMF- H2O was allowed to react 
with HCl at room temperature (Scheme 3.4). The formation of 3-2 was amenable to KBr 
FTIR monitoring (i.e. appearance of sulfone stretch at 1443, 1287 cm-1). Condensation of 
3-2 with an aldehyde and an amide gave resin 3-3 which was monitored with FTIR 
(appearance of the carbonyl stretch at 1650 cm-1). We next proceeded to generate the  
α-ketoamide in situ by treating resin 3-3 with excess TEA and an aldehyde in the 
presence of a thiazolium catalyst in CH2Cl2 at 35oC for 10 hours. Concentration of the 
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reaction mixture followed by the addition of ethanol/amine and refluxing under nitrogen 
condition gave 3-5. The overall yields obtained were 24-40% yield (Table 3.1), 
indicating an average yield of greater than 70% for each step of the four solid-phase 
reactions. 
 
In addition to the synthesis of imidazoles, we have also examined the application of this 
methodology for the synthesis of other 1,3-azoles. The α-ketoamide generated in situ 
from resin 3-3 was treated with PPh3/I2 or Lawesson’s reagent to furnish the 















3-5 3-6 3-7  
compd R1 R2 R3 R4 yield (%)a
3-5a C6H5 C6H5 C5H5N H 37 
3-5b C6H5 C6H5 C5H5N CH2CH2OH 35 
3-5c C6H5 C6H5 C5H5N C4H9 34 
3-5d C6H5 H C5H5N H 39 
3-5e C6H5 H C5H5N CH2CH2OH 40 
3-5f C6H5 CH3 C5H5N C4H9 31 
3-5g C6H5 CH3 CH=CHC6H5 C4H9 24 
3-5h p-FC6H4 C6H5 C5H5N C4H9 27 
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3-5i C6H5 CH3 C5H5N CHCH3(C2H5) 30 
3-5j C6H5 C6H11 CH=CHC6H5 H 24 
3-5k CH2CH(CH3)2 C6H5 C5H5N C4H9 27 
3-5l C2H5 C6H5 C5H5N CH2CH2OH 24 
3-6a C6H5 C6H5 C5H5N  27 
3-6b C6H5 C6H11 C5H5N  24 
3-6c p-FC6H4 C6H5 CH=CHC6H5  19 
3-7a C6H5 C6H5 C5H5N  32 
3-7b C6H5 C6H11 C5H5N  30 
3-7c p-FC6H4 C6H5 CH=CHC6H5  22 
a Purified overall yield calculated based on the loading of the resin. Purities of >95% as 
evaluated by NMR. 
Table 3.1 Library of imidazoles, thiazoles and oxazoles 
 
3.3 Conclusion 
In summary, we have demonstrated a traceless solid-phase synthesis of substituted 
imidazoles, oxazoles and thiazoles. The use of a sulfone moiety as a linker in the reaction 
benefits the solid-phase synthetic route as it not only makes isolation of the product easier 
but its chemical versatility also adds to the diversity of the library. 
 
3.4 Experimental section 
3.4.1 General procedure for the preparation of polymer-supported phenylsulfinic 
Acid. 3-1 (1g, 2.1mmol) was swollen in 20 mL DMF by gently stirring the resin-DMF 
mixture at room temperature for 0.5 hour. Concentrated HCl (6 equiv.) was added and the 
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reaction mixture was stirred at room temperature for 4 hours. After which, the mixture 
was filtered and the resin washed sequentially with DMF (20 mL*2), H2O (20 mL*2), 
EtOH (20 mL*2), DCM (20 mL*2) and ether (20 mL*2), and dried for 2 hours in a 
vacuum oven at 40°C to afford resin 3-2.  
 
3.4.2 General procedure for the synthesis of polymer supported arylsulphonylamide. 
Resin 3-2 was swollen in a mixture of 25 mL anhydrous acetonitrile and 25 mL 
anhydrous toluene at room temperature for 0.5 hour. The resin was sequentially treated 
with aldehyde (6 equiv.), amide (15 equiv.) and chlorotrimethylsilane (6.6 equiv.). The 
reaction mixture was gently stirred at 80oC for 8 hours. After which, the mixture was 
filtered and the resin was washed sequentially with DMF (20 mL*2), H2O (20 mL*2), 
EtOH (20 mL*2), DCM (20 mL*2) and ether (20 mL*2), and dried overnight in a 
vacuum oven at 40°C to afford resin 3-3. 
 
3.4.3 General procedure for the synthesis of 1,2,4,5-tetrasubsituted imidazoles. A 50 
mL flask was charged with resin 3-3 (0.5g, 1 equiv.) and the thiazolium catalyst (20 
mol%) and purged with nitrogen for 15 minutes. To the flask was added CH2Cl2 (25 mL) 
followed by the aldehyde (8 equiv.) and the resulting mixture was gently stirred at 35 oC 
for 10 hours. After which, the solvent was removed by concentration and the residual 
mixture was treated sequentially with ethanol (25 mL), acetic acid (8 equiv.) and amine 
(8 equiv.). The reaction mixture was then refluxed for a further 12 hours. The resin was 
filtered and washed with MeOH (20 mL*3). The combined organic layer was 
concentrated on a rotavapor and purified by flash column chromatography to give 3-5.  
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 3.4.4 General procedure for the synthesis of 2,4,5-trisubstituted thiazoles.  
A 50 mL flask was charged with resin 3-3 (0.5 g) and the thiazolium catalyst (20 mol%) 
and purged with nitrogen for 15 minutes. To the flask was added anhydrous CH2Cl2 
(25ml) followed by the aldehyde (8 equiv.) and the resulting mixture was stirred at 35 oC 
for 11 hours. Triethylamine (20 equiv.) was added via a syringe and the reaction mixture 
was allowed to continue stirring overnight at 35 oC. After which, the solvent was 
removed by simple concentration followed by the addition of toluene (25 mL) and 
Lawesson’s reagent (6 equiv.). The reaction mixture was then refluxed overnight. The 
resin was removed by filtration and washed with MeOH (20 mL*3). The combined 
organic layer was concentrated on a rotavapor and purified by flash column 
chromatography to give 3-6.  
 
3.4.5 General procedure for the synthesis of 2,4,5-trisubstituted oxazoles.  
A 50 mL flask was charged with resin 3-3 (0.5 g) and the thiazolium catalyst (20 mol%) 
and purged with nitrogen for 15 minutes. To the flask was added anhydrous CH2Cl2 
(25ml) followed by the aldehyde (8 equiv.) and the resulting mixture was stirred at 35 oC 
for 11 hours. Triethylamine (20 equiv.) was added via a syringe and the reaction mixture 
was allowed to continue stirring overnight at 35 oC. After which, iodine (5 equiv.) and 
triphenylphospine (5 equiv.) were added and the mixture was stirred at ambient 
temperature for another 20 hours. The resin was then removed by filtration and washed 
with MeOH (20 mL*3). The combined organic layer was concentrated on a rotavapor and 




4-(2,5-Diphenyl-3H-imidazol-4-yl)pyridine (3-5a): 1H NMR (CDCl3): δ 8.44 (m, 2H, 
ArH), 8.02 (m, 2H, ArH), 7.98-7.95 (m, 2H, ArH), 7.59-7.48 (m, 8H, ArH). 13C NMR 
(CDCl3): δ 150.7, 150.5, 142.9, 138.1, 133.0, 132.1, 131.0, 130.8, 130.6, 129.1, 128.7, 






2-(2,4-Diphenyl-5-pyridin-4-yl-imidazol-1-yl)ethanol (3-5b): 1H NMR (CDCl3): δ 8.59 
(m, 2H, ArH), 7.46-7.35 (m, 6H, ArH), 7.32 (m, 2H, ArH), 7.23-7.21 (m, 4H, ArH), 4.06 
(t, J = 5.92 Hz, 2H, CH2), 3.42 (t, J = 5.92 Hz, 2H, CH2). 13C NMR (CDCl3): δ 150.1, 
149.2, 139.8, 139.3, 133.5, 130.9, 130.8, 130.4, 129.3, 128.7, 128.3, 127.5, 127.1, 125.6, 





4-(3-Butyl-2,5-diphenyl-3H-imidazol-4-yl)pyridine (3-5c): 1H NMR (CDCl3): δ 8.59 
(m, 2H, ArH), 7.69 (m, 2H, ArH), 7.50-7.46 (m, 5H, ArH), 7.35 (m, 2H, ArH), 7.26-7.23 
(m, 3H, ArH), 3.96 (t, J = 8.01 Hz, 2H, CH2), 1.29 (m, 2H, CH2), 0.97 (m, 2H, CH2), 0.62 
(t, J = 7.32 Hz, 3H, CH3). 13C NMR (CDCl3): δ 150.6, 149.1, 139.9, 139.4, 133.8, 131.0, 
130.8, 129.2, 129.1, 128.7, 128.2, 127.3, 126.9, 125.3, 44.8, 32.5, 19.4, 13.2. HRMS (EI) 





4-(4-Phenyl-1H-imidazol-5-yl)pyridine (3-5d): 1H NMR (DMSO-d6): δ 12.74 (1H, br, 
NH ), 8.44 (m, 2H, ArH), 7.88 (s, 1H, CH), 7.45 (m, 7H, ArH). 13C (DMSO-d6): δ 149.7, 
149.0, 142.3, 136.5, 134.7, 128.8, 128.3, 127.9, 120.8, 120.5. HRMS (EI) calcd. for 








2-(4-Phenyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)ethanol (3-5e): 1H (DMSO-d6): δ 8.68 
(m, 2H, ArH ), 7.89 (s, 1H, CH), 7.41 (m, 2H, ArH), 7.32 (m, 2H, ArH), 7.25-7.15 (m, 
3H, ArH), 4.99 (t, J = 5.22 Hz, 1H, OH), 3.91 (t, J = 5.57 Hz, 2H, CH2), 3.48 (dd, J = 
5.22, 5.57 Hz, 2H, CH2) . 13C (DMSO-d6): δ 150.4, 138.9, 138.8, 138.0, 134.5, 130.5, 





4-(3-Butyl-2-methyl-5-phenyl-3H-imidazol-4-yl)pyridine (3-5f): 1H NMR (CDCl3): δ 
8.72 (m, 2H, ArH), 7.40 (m, 2H, ArH), 7.38-7.23 (m, 5H, ArH), 3.82 (t, J = 7.66 Hz, 2H, 
CH2), 2.63 (s, 3H, CH3), 1.50 (m, 2H, CH2), 1.21 (m, 2H, CH2), 0.81 (t, J = 7.32 Hz, 3H, 
CH3). 13C NMR (CDCl3): δ 150.6, 150.3, 145.3, 138.7, 136.0, 131.7, 128.4, 127.4, 127.1, 







1-Butyl-2-methyl-4-phenyl-5-styryl-1H-imidazole (3-5g): 1H NMR (CDCl3): δ 7.82 (m, 
1H, ArH), 7.71 (m, 2H, ArH), 7.38-7.27 (m, 7H, ArH), 6.96 (d, J = 16.47 Hz, 1H, CH), 
6.75 (d, J = 16.47 Hz, 1H, CH), 3.96 (t, J = 7.63 Hz, 2H, CH2), 2.47 (s, 3H, CH3), 1.76 
(m, 2H, CH2), 1.43 (m, 2H, CH2), 0.99 (t, J = 6.83 Hz, 3H, CH3) . 13C NMR (CDCl3): δ 
147.6, 137.6, 134.5, 131.5, 131.4, 131.0, 129.1, 129.0, 128.7, 128.5, 128.0, 126.8, 126.1, 




4-[3-Butyl-5-(4-fluoropenyl)-2-phenyl-3H-imidazol-4-yl]pyridine (3-5h): 1H NMR 
(CDCl3): δ 8.72 (m, 2H, ArH), 7.66 (m, 2H, ArH), 7.47-7.41 (m, 5H, ArH), 7.35 (m, 2H, 
ArH), 6.95 (m, 2H, ArH), 3.97 (t, J = 8.01 Hz, 2H, CH2), 1.26 (m, 2H, CH2), 0.97 (m, 2H, 
CH2), 0.61 (t, J = 7.32 Hz, 3H, CH3). 13C NMR (CDCl3): δ 162.9, 150.2, 130.5, 129.7, 
129.1, 129.0, 128.9, 128.8, 128.6, 125.1, 117.5, 117.2, 115.2, 114.9, 44.7, 32.3, 19.2, 13.0. 




4-(3-sec-Butyl-2-methyl-5-phenyl-3H-imidazol-4-yl)pyridine (3-5i): 1H NMR (CDCl3): 
δ 8.69 (m, 2H, ArH), 7.33 (m, 2H, ArH), 7.26-7.23 (m, 3H, ArH), 7.18 (m, 2H, ArH), 
3.94 (m, 1H, CH), 2.59 (s, 3H, CH3), 1.86-1.70 (m, 2H, CH2), 1.44 (d, J = 6.96 Hz, 3H, 
CH3), 0.78 (t, J = 7.32 Hz, 3H, CH3). ). 13C NMR (CDCl3): δ 150.5, 150.4, 144.9, 140.9, 
129.2, 128.2, 126.9, 126.6, 126.2, 121.5, 53.8, 28.7, 20.5, 15.7, 11.1. HRMS (EI) calcd. 





2-(2-Cyclohexyl-4-phenyl-5-styrylimidazol-1-yl)ethanol (3-5j): 1H NMR (CDCl3): δ 
7.59-7.51 (m, 7H, ArH), 7.41-7.38 (m, 3H, ArH), 6.99 (d, J = 16.5 Hz, 1H, CH), 6.81 (d, 
J = 16.5 Hz, 1H, CH), 2.90 (m, 1H, CH), 2.20-2.13 (m, 2H), 1.94-1.86 (m, 2H), 1.79-1.62 
(m, 3H), 1.50-1.26 (m, 3H). 13C NMR (CDCl3): δ 136.0, 134.5, 132.7, 130.1, 129.4, 
129.2, 128.8. 128.6, 128.1, 127.6, 127.2, 126.7, 112.6, 37.8, 30.8, 25.9, 25.7. HRMS (EI) 




4-(3-Butyl-5-isobutyl-2-phenyl-3H-imidazol-4-yl)pyridine (3-5k): 1H NMR (CDCl3): 
δ 8.71 (m, 2H, ArH), 7.52(m, 5H, ArH), 7.28 (m, 2H, ArH), 3.98 (d, J = 7.32 Hz, 2H, 
CH2), 2.44 (d, J = 7.31 Hz, 2H, CH2), 1.19 (m, 2H, CH2), 0.97 (m, 3H, CH and CH2), 
0.84 (d, J = 6.62 Hz, 6H, CH3), 0.58 (t, J = 6.97 Hz, 3H, CH3) .13C NMR (CDCl3): 150.1, 
149.6, 140.8, 131.8, 129.1, 128.8, 127.3, 127.0, 124.5, 121.8, 44.9, 36.2, 32.3, 28.9, 22.4, 





2-(4-Ethyl-2-phenyl-5-pyridin-4-yl-imidazol-1-yl)ethanol (3-5l): 1H NMR (CDCl3): δ 
8.58 (m, 2H, ArH), 7.70 (m, 2H, ArH), 7.34 (m, 5H, ArH), 3.63 (t, J = 5.58 Hz, 2H, CH2), 
3.43 (t, J = 5.58 Hz, 2H, CH2), 3.09 (q, J = 7.32 Hz, 2H, CH2), 1.21 (t, J = 7.32 Hz, 3H, 
CH3). 13C NMR (CDCl3): 150.9, 149.7, 143.9, 131.4, 129.4, 126.8, 124.8, 124.5, 123.0, 
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4-(2,4-Diphenyl-thiazol-5-yl)pyridine (3-6a): 1H NMR (CDCl3): δ 8.61 (m, 2H, ArH), 
7.71-7.69 (m, 2H, ArH), 7.41-7.37 (m, 6H, ArH), 7.30 (m, 2H, ArH), 7.24 (m, 2H, ArH). 
13C NMR (CDCl3): δ 177.1, 151.9, 150.8, 140.9, 140.7, 134.6, 132.5, 132.2 129.2, 128.6, 




4-(2-Cyclohexyl-4-phenyl-thiazol-5-yl)-pyridine (3-6b): 1H NMR (CDCl3): δ 8.51 (m, 
2H, ArH), 7.50-7.49(m, 2H, ArH), 7.35-7.33 (m, 3H, ArH), 7.23 (m, 2H, ArH), 3.13-3.03 
(m, 1H, CH), 2.28-2.18(m, 2H), 1.93-1.72(m, 3H), 1.68-1.27(m, 5H). 13C NMR (CDCl3): 
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δ 176.6, 151.4, 150.1, 140.4, 134.6, 129.2, 128.6, 128.5, 128.4, 123.9, 43.1, 33.8, 26.1, 





4-(4-Fluorophenyl)-2-phenyl-5-styrylthiazole (3-6c): 1H NMR (CDCl3): δ 7.48-7.42 
(m, 6H, ArH), 7.30-7.11 (m, 9H, ArH and CH), 6.95 (d, J = 16.6 Hz, CH). 13C NMR 
(CDCl3): δ 168.2, 162.7, 151.4, 142.9, 136.0, 134.5, 133.1, 129.5, 129.2, 128.9, 128.7, 





4-(2,4-Diphenyl-oxazol-5-yl)pyridine (3-7a): 1H NMR (CDCl3): δ 8.66 (m, 2H, ArH), 
7.75-7.72 (m, 2H, ArH), 7.45-7.43 (m, 6H, ArH), 7.33 (m, 2H, ArH), 7.27 (m, 2H, ArH). 
13C NMR (CDCl3): δ 168.3, 150.2, 142.0, 138.9, 136.4, 132.0, 129.6, 129.0, 128.6, 128.4, 




4-(2-Cyclohexyl-4-phenyloxazol-5-yl)pyridine (3-7b): 1H NMR (CDCl3): δ 8.56 (m, 
2H, ArH), 7.65-7.62(m, 2H, ArH), 7.45 (m, 2H, ArH), 7.44-7.40 (m, 3H, ArH), 2.91 (m, 
1H, CH), 2.21-2.11(m, 2H, CH2), 1.95-1.84(m, 2H, CH2), 1.80-1.62(m, 3H), 1.50-1.26(m, 
3H). 13C NMR (CDCl3): δ 168.2, 150.2, 142.0, 138.9, 136.4, 132.1, 128.9, 128.8, 128.3, 





4-(4-Fluorophenyl)-2-phenyl-5-styryloxazole (3-7c): 1H NMR (CDCl3): δ 7.50-7.38 (m, 
7H, ArH), 7.34-7.15 (m, 8H, ArH and CH), 7.06 (d, J = 16.6 Hz, 1H, CH). 13C NMR 
(CDCl3): δ 166.1, 163.4, 150.2, 142.0, 135.9, 134.4, 132.7, 130.7, 130.2, 129.4, 129.2, 








































4.1.1 Importance of 3,4-dihydropyrimidine-2-ones 
3,4-Dihydropyrimidine-2-one derivatives are useful targets in chemical synthesis as they 
have been associated with a diverse range of therapeutic and medicinal properties.73 
Several marine alkaloids containing the dihydropyrimidinone scaffold have also been 
shown to possess antiviral, antitumor, antibacterial and anti-inflammatory activities74 and, 
in particular, the batzelladine alkaloids are known to be potent HIV gp-120-CD4 
inhibitors.75 This multifaceted profile bodes well for the interaction of such 
heterocycles(Figure 4.1) with a variety of biological targets which has consequently led 
to the development of a number of lead compounds based on this structural core.73   
 
Figure 4.1 Structures of some calcium channel modulators 
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4.1.2 General synthetic methods in solution phase chemistry 
Spurred by the diverse biological activities of these compounds, various synthetic 
methods for the preparation of 3,4-dihydropyrimidine-2-ones on solution-phase have 
been examined.76b Nevertheless the method (Figure 4.2) of choice for the synthesis of 
most dihydropyrimidine involves the acid-catalyzed cyclocondensation of a 1,3-
dicarbonyl component with an aromatic aldehyde and urea or thiourea derivative, namely 
Biginelli reaction.76a A major drawback of the Biginelli protocols, using ethanol and 
catalytic HCl as reaction medium, has been the low yields that were frequently 
encountered when using sterically more demanding aldehydes or thioureas. In recent 
years, these problems have been largely resolved by the development of improved and 
more robust reaction conditions, involving e.g. Lewis-acid catalysis, solvent-free 
procedures or microwave-enhanced protocols.76b 
 
Figure 4.2 The Biginelli dihydropyrimidine synthesis   
 
4.1.3 Solid phase synthesis of 3,4-dihydropyrimidine-2-ones 
Various synthetic methods(Scheme 4.1) for the preparation of 3,4-dihydropyrimidine-2-
ones on solid-phase have been examined.77 Amongst them, only one reports on the 
traceless synthesis of these compounds.77d In this paper(Scheme 4.2), polymer-bound 
thiourea was reacted with Knoevenagel condensation products (prepared separately by 
solution-phase synthesis), using the Atwal modification of the Biginelli reaction, to give 
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pyrimidines which were, in turn, converted to 3,4-dihydropyrimidine-2-ones during 
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Hamper, B. C.; Gan, K. Z.; Owen, T. J. Tetrahedron Lett. 1999, 40, 4973-4976 
Scheme 4.1 Two examples of solid phase synthesis of 3,4-dihydropyrimidine-2-ones 
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 Kappe, C. O. Bioorg. Med. Chem. Lett. 2000, 10, 49-51. 
Scheme 4.2 Traceless synthesis of 3,4-dihydropyrimidine-2-ones by Kappe 
 
4.1.4 Our purpose 
For the preparation of large libraries without massive parallel synthetic effort, it would be 
desirable if all steps of the reaction could be carried out on a solid-phase resin. To our 
knowledge, such a process resulting in the traceless solid-phase synthesis of 3,4-
dihydropyrimidine-2-ones has not been previously demonstrated. We herein describe the 
application of 4-1 for a convenient traceless solid-phase approach to 3,4-
dihydropyrimidine-2-ones. Key steps in the synthesis are (i) sulfinate acidification, (ii) 
condensation of urea or thiourea with aldehydes and sulfinic acid, and (iii) traceless 
product release by a one-pot cyclization-dehydration process (Scheme 4.3). Since a 
variety of reagents can be used in steps (ii) and (iii), the overall strategy appears to be 
applicable to library generation. 
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 Scheme 4.3 Solid phase synthesis of 3,4-dihydropyridine-2-ones 
 
4.2 Results and discussion 
4.2.1 Solution phase synthesis of 3,4-dihydropyridine-2-ones. Prior to the solid-phase 
synthesis, preliminary solution-phase studies were carried out to survey the requisite 
reaction conditions and establish the modifications for the solid-phase synthesis. 
Benzenesulfinic acid 4-7 was prepared in 93% yield by treating sodium benzenesulfinate 
with HCl in water at room temperature (Scheme 4.4). For the synthesis of 
(benzenesulfonylphenylmethyl)-thiourea and –urea 4-8, a three component condensation 
of thiourea or urea with aldehyde and benzenesulfinic acid was used. Treatment of 
thiourea with equimolar ratios of benzenesulfinic acid and benzaldehyde in DMF for 16 
hours afforded 4-8a in 94% yield. However, attempts to prepare 
(benzenesulfonylphenylmethyl)urea 4-8b using the same reaction conditions gave 
significantly more N,N’-bi(benzenesulfonylphenylmethyl)urea (21%). To effect the 
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formation of 4-8b, the proportion of urea used was increased and at 5 equimolar ratio, 4-
8b was obtained in 89% yield. Subsequent treatment of 4-8 with the sodium enolate of 
ethyl acetoacetate (which was generated in situ by the treatment of ethyl acetoacetate 
with NaH/CH3CN) at room temperature for 8 hours followed by TsOH gave 4-9 in 86% 
yield. We found that t-BuOK/DMSO and KOH/EtOH were equally effective in 




Scheme 4.4 Solution phase synthesis of 3,4-dihydropyridine-2-ones 
 
4.2.2 Solid phase synthesis of 3,4-dihydropyridine-2-ones. With the solution-phase 
pathway to 3, 4-dihydropyrimidone established, we proceeded to develop the solid-phase 
route to these compounds. Due to the poor swelling ability of polystyrene/1% 
divinylbenzene (4-1, 100-200 mesh) in water, a DMF-H2O (v/v 3:1) mixture was used as 
the solvent for the preparation of 4-2. The formation of 4-2 was amenable to KBr FTIR 
monitoring for the appearance of the sulfone stretch (νasym 1443 and νsym 1287 cm-1). 
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Condensation of 4-2 with an aldehyde and an amide gave resin 4-3 which was easily 
monitored by IR spectroscopy for the appearance of the carbonyl stretch (νmax 1610cm-1). 
Subsequent treatment of resin 4-3 with the potassium enolates of 1,3-dicarbonyl 
compounds or β-ketoesters (generated in situ by treating the latter reagents with 
KOH/EtOH) for 10 hours at ambient temperature followed by the addition of TsOH.H2O 
and 3 hours of reflux gave 4-4 through a one-pot cyclization-dehydration process. To 
illustrate the versatility of this chemistry, a library of 14 compounds (4-4a-4-4n in 
Figure 4.3) were prepared. The overall yields obtained were 20-40% (purities of >95% 
by NMR). 
 
We have also examined the application of this methodology for the synthesis of 
dihydropyrimidinecarboxylic acids 4-5. Cyclization of resin 4-3 with a mixture of 
pyrrolidine and α-ketoacid in ethanol followed by the addition of TsOH.H2O gave the 
ester form of 4-5 (Figure 4.3 4-5a-4-5b) in 35-39% overall yield. However when THF 
was used as the solvent, the free carboxylic acid form of 4-5 was obtained (4-5c and 4-5d 
in Figure 4.3). 
 
4.3 Conclusion  
In summary, we have demonstrated a general protocol for the solid-phase synthesis of 
3,4-dihydropyrimidine-2-ones using 4-1 was a traceless linker. Products 4-4 and 4-5 
precipitated readily from cold water and could be expediently purified without the need 
for column chromatography. Since a variety of reagents can be used in steps (ii) and (iii), 
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Figure 4.3 Library of 3,4-dihydropyridine-2-ones 
 
4.4 Experimental section 
 
4.4.1 General procedures.  1H NMR and 13CNMR spectra were measured at 298K on 
Bruker DPX 300 Fourier Transform spectrometer. Chemical shifts were reported in δ 
(ppm), relative to the internal standard of tetramethylsilane (TMS). All Infra-red (IR) 
spectra were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were performed 
on VG Micromass 7035 spectrometer under electron impact (EI). All chemical reagents 
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were obtained from commercial suppliers and used without further purification. 
Analytical TLC was carried out on pre-coated plates (Merck silica gel 60,F254) and 
visualized with UV light.  
 
4.4.2 Synthesis of phenylsulfinic acid (4-7). Sodium benzenesulfinate (2.46g, 15mmol) 
was dissolved in 150mL water and the mixture was stirred for 20-30 min until a clear 
solution was obtained. Diethylether (60mL) was added followed by the slow addition of 
1.6mL of concentrated aqueous hydrochloric acid (HCl) (15mmol) over 2 min. The 
mixture was stirred for an additional 20-30 min, transferred to a separatory funnel and the 
aqueous layer was removed. The organic layer was concentrated on a rotary evaporator 
and the white solid obtained was dried under vacuum to give 4-7 (1.98g, 13.95mmol).  
 
4.4.3 Synthesis of (benzenesulfonylphenylmethyl)thiourea (4-8a). To a mixture of  
benzaldehyde (0.53g, 5 mmol) in DMF (20mL) was added thiourea (0.38g, 5mmol) 
followed by the phenylsulfinic acid (0.78g, 5mmol). The resulting suspension was stirred 
at room temperature for 16h. The solvent was removed under high vacuum and 20mL 
water was added to the residual mixture. The mixture was cooled to 0oC and the solid 
which precipitated was collected by filtration, washed carefully with ice water, 
diethylether and dried to give 4-8 as a white solid (1.30g, 4.25mmol). The obtained 
product was used in the pyrimidine synthesis without further purification. 
 
4.4.4 Synthesis of 5-ethoxymethyl-6-methyl-4-phenyl-3,4-dihydro-1H-pyrimidine-2-
thione (4-9a). To a stirred solution of NaH (0.168g, 7 mmol) in CH3CN (10mL) was 
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slowly added a solution of ethyl acetoacetate (0.9g, 7mmol) in CH3CN (15mL) and the 
resulting mixture was stirred for 30 minutes. After which, 4-8a (1.53g, 5mmol) was 
added and the reaction mixture was stirred for 4.5 h at room temperature. The mixture 
was acidified by addition of TsOH.H2O (0.94 g, 5mmol) and refluxed for 2 hours. The 
solvent was removed under reduced pressure and the solid residue was treated with water 
(20mL). The mixture was cooled to 0oC and the precipitate which formed was filtered, 
washed carefully with ice water, diethylether and dried to give 4-9a (1.13g, 4.31mmol). 
 
4.4.5 Synthesis of polymer-supported phenylsulfinic acid (4-2). Polystyrene/1% 
divinylbenzene sodium sulfinate 4-1 (1g, 2.1mmol) was swollen in 20mL DMF-H2O 
mixture (v/v 3:1) for 0.5 hours. The resin was then treated with concentrated HCl (6 
equiv. 12.6mmol) and the reaction mixture was stirred at room temperature for 4 hours. 
After which, the resin was filtered, washed sequentially with DMF (20mL*2), H2O 
(20mL*2), EtOH (20mL*2), DCM (20mL*2) and ether (20mL*2), and dried in a vacuum 
oven at 35°C to afford resin 4-2. 
 
4.4.6 General procedure for the preparation of polymer-supported 
(benzenesulfonylsubstituted)-thiourea and -urea (4-3). Resin 4-2 (1g, 2.1mmol) was 
swollen in 25mL anhydrous DMF at the room temperature for 0.5 hours. The resin was 
sequentially treated with aldehyde (6 equiv.) and thiourea or urea (12 equiv.) and the 
reaction mixture was stirred at room temperature for 24 hours. After which, the resin was 
filtered, washed sequentially with DMF (20mL*2), H2O (20mL*2), EtOH (20mL*2), 
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DCM (20mL*2) and ether (20mL*2), and dried overnight in a vacuum oven at 45°C to 
afford resin 4-3. 
 
4.4.7 General procedure for the preparation of substituted 3,4-dihydro-1H-
pyrimidine-2-ones (4-4). To a stirred solution of KOH (0.94g, 16.8mmol) in ethanol 
(15mL) was added a solution of 1,3-dione or acetoacetate (8 equiv. ) in ethanol (15mL) at 
room temperature and the resulting mixture was stirred for 30 minutes. Resin 4-3 (1g, 
2.1mmol) was added and the mixture was allowed to continue stirring overnight at room 
temperature. After which, TsOH.H2O (8 equiv.) was added and the mixture was refluxed 
for an additional 3 hours. When the mixture was still hot, it was suction filtered and 
washed with copious hot ethanol. The combined mixture was concentrated under reduced 
pressure and the residue obtained was dissolved in water (20mL). The aqueous solution 
was cooled to 0oC and the precipitate formed was filtered, washed carefully with ice 
water, diethylether and dried in the vacuum oven at 450C over night to give 4-4. 
 
4.4.8 General procedure for the preparation of 5,6-disubstituted-2-thioxo-1,2,3,6-
tetrahydro-pyrimidine-4-carboxylic acid  and 5,6-disubstituted-2-oxo-1,2,3,6-
tetrahydro-pyrimidine-4-carboxylic acid (4-5). Resin 4-3 (1g, 2.1mmol) was swollen 
in THF (25mL) at the room temperature for 0.5 hours. Pyrrolidine (9 equiv.) and 
phenylpyruvic acid or 2-oxobutyric acid (8 equiv.) were added and the solution was 
stirred at room temperature for 2 hours. After which, TsOH (12 equiv.) was added and 
the mixture was refluxed for a further 24 hours. When the mixture was still hot, it was 
suction filtered and washed with copious hot THF. The combined mixture was 
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concentrated under reduced pressure and the residue obtained was dissolved in water 
(20mL). The mixture was cooled to 00C and the precipitate obtained was filtered, washed 











ethyl ester 4-4a:  1H NMR (DMSO-d6): δ 10.39 (s, 1H, NH), 9.63 (s, 1H, NH), 7.58 (m, 
1H, ArH), 6.38 (m, 1H, ArH), 6.14 (m, 1H, ArH), 5.22 (m, 1H, CH), 4.04 (m, 2H, CH2), 
2.28 (s, 3H, CH3), 1.13 (t, J=7.31 Hz, 3H, CH3). 13C NMR (DMSO-d6): 174.9, 164.7, 
154.5, 145.8, 142.5, 110.4, 106.1, 98.2, 59.5, 47.6, 17.0, 14.0. HRMS (EI): Calcd for 












1H NMR (DMSO-d6): δ 10.35 (s, 1H, NH), 9.74 (s, 1H, NH), 7.59 (m, 1H, ArH), 6.38 (m, 
1H, ArH), 6.17 (m, 1H, ArH), 5.35 (m, 1H, CH), 2.29 (s, 3H, CH3), 2.19 (s, 3H, CH3). 
13C NMR (DMSO-d6): 194.3, 174.9, 154.6, 145.1, 142.8, 110.5, 108.2, 106.5, 47.8, 30.0, 










5-Acetyl-4-furan-2-yl-6-methyl-3,4-dihydro-1H-pyrimidin-2-one 4-4c: 1H NMR 
(DMSO-d6): δ 9.22 (s, 1H, NH), 7.84 (s, 1H, NH), 7.56 (m, 1H, ArH), 6.35 (m, 1H, ArH), 
6.12 (m, 1H, ArH), 5.31 (m, 1H, CH), 2.24 (s, 3H, CH3), 2.16 (s, 3H, CH3). 13C NMR 
(DMSO-d6): 193.7, 155.8, 152.3, 148.6, 142.2, 110.2, 107.2, 105.5, 47.8, 29.8, 18.8. 










4-Ethyl-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl 
ester 4-4d: 1H NMR (DMSO-d6): δ 10.07 (s, 1H, NH), 9.21 (s, 1H, NH), 4.08 (m, 3H, 
CH and OCH2), 2.20 (s, 3H, CH3), 1.43 (m, 2H, CH2), 1.19 (t, J=6.97 Hz, 3H, CH3), 0.78 
(t, J=7.32 Hz, 3H, CH3). 13C NMR (DMSO-d6): 174.8, 164.9, 144.9, 99.8, 59.1, 51.3, 









4-Ethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
4-4e: 1H NMR (DMSO-d6): δ 8.90 (s, 1H, NH), 7.26 (s, 1H, NH), 4.05 (m, 3H, CH and 
OCH2), 2.16 (s, 3H, CH3), 1.42 (m, 2H, CH2), 1.18 (t, J=6.96 Hz, 3H, CH3), 0.79 (t, 
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J=7.32 Hz, 3H, CH3). 13C NMR (DMSO-d6): 165.4, 152.7, 148.3, 98.7, 58.9, 51.3, 29.5, 










1-(4-Ethyl-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-ethanone 4-4f: 1H 
NMR (DMSO-d6): δ 10.03 (s, 1H, NH), 9.30 (s, 1H, NH), 4.14 (m, 1H, CH), 2.22 (m, 6H, 
CH3), 1.37 (m, 2H, CH2), 0.78 (t, J=7.32 Hz, 3H, CH3). 13C NMR (DMSO-d6): 194.7, 
174.8, 143.9, 110.7, 51.7, 30.1, 28.9, 17.9, 8.2. HRMS (EI): Calcd for C9H14N2OS:    










6-Methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl 
ester 4-4g: 1H NMR (DMSO-d6): δ 10.31 (s, 1H, NH), 9.63 (s, 1H, NH), 7.29 (m, 5H, 
ArH), 5.18 (m, 1H, CH), 4.02 (q, J=6.97 Hz, 2H, OCH2), 2.29 (s, 3H, CH3), 1.10 (t, 
J=6.97 Hz, 3H, CH3). 13C NMR (DMSO-d6): 174.2, 165.0, 144.9, 143.4, 128.4, 127.5, 














6-Methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
4-4h: 1H NMR (DMSO-d6): δ 9.17 (s, 1H, NH), 7.73 (s, 1H, NH), 7.25 (m, 5H, ArH), 
5.14 (m, 1H, CH), 3.98 (q, J=6.96 Hz, 2H, OCH2), 2.25 (s, 3H, CH3), 1.09 (t, J=6.96 Hz, 
3H, CH3). 13C NMR (DMSO-d6): 165.2, 152.0, 148.2, 144.8, 128.3, 127.1, 126.1, 99.2, 










5-Acetyl-6-methyl-4-phenyl-3,4-dihydro-1H-pyrimidin-2-one 4-4i: 1H NMR (DMSO-
d6): δ 9.16 (s, 1H, NH), 7.80 (s, 1H, NH), 7.25 (m, 5H, ArH), 5.25 (m, 1H, CH), 2.28 (s, 
3H, CH3), 2.10 (s, 3H, CH3). 13C NMR (DMSO-d6): 194.0, 151.9, 147.8, 144.1, 128.3, 











4,6-Diphenyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 4-
4j: 1H NMR (DMSO-d6): δ 8.68 (s, 1H, NH), 8.58 (s, 1H, NH), 7.95 (m, 2H, ArH), 7.67-
7.32 (m, 8H, ArH), 5.01 (m, 1H, CH), 4.13 (q, J=6.97 Hz, 2H, OCH2), 1.17 (t, J=6.97 Hz, 
3H, CH3). 13C NMR (DMSO-d6): 176.8, 167.4, 141.7, 138.8, 133.7, 128.7, 128.3, 128.1, 
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127.9, 127.6, 126.1, 81.2, 60.5, 59.4, 13.9. HRMS (EI): Calcd for C19H18N2O2S: 









2-Oxo-4,6-diphenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 4-4k: 
1H NMR (DMSO-d6): δ 9.73 (s, 1H, NH), 9.28 (s, 1H, NH), 8.04 (m, 3H, ArH), 7.71-
7.37 (m, 7H, ArH), 4.88 (m, 1H, CH), 3.79 (q, J=6.97 Hz, 2H, OCH2), 0.78 (t, J=6.97 Hz, 
3H, CH3). 13C NMR (DMSO-d6): 165.3, 153.2, 147.5, 143.4, 135.0, 129.5, 128.8, 128.2, 













ethanone 4-4l: 1H NMR (DMSO-d6): δ 10.15 (s, 1H, NH), 9.27 (s, 1H, NH), 6.91 (m, 1H, 
ArH), 6.57 (m, 1H, ArH), 6.46 (m, 1H, ArH), 5.50 (m, 1H, CH), 3.80 (s, 3H, CH3), 3.74 
(s, 3H, CH3), 2.28 (s, 3H, CH3), 2.05 (s, 3H, CH3). 13C NMR (DMSO-d6): 195.1, 173.9, 
160.3, 157.2, 143.5, 129.7, 128.1, 122.6, 104.9, 98.6, 55.5, 55.2, 48.7, 29.3, 17.7. HRMS 









6-Methyl-4-styryl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl 
ester 4-4m: 1H NMR (DMSO-d6): δ 10.30 (s, 1H, NH), 9.46 (s, 1H, NH), 7.34 (m, 5H, 
ArH), 6.38 (d, J=15.68 Hz, 1H, CH), 6.18 (dd, J=15.68, 5.92 Hz, 1H, CH), 4.76 (m, 1H, 
CH), 4.12 (q, J=6.96 Hz, 2H, CH2), 2.25 (s, 3H, CH3), 1.20 (t, J=6.96 Hz, 3H, CH3). 13C 
NMR (DMSO-d6): 175.0, 164.9, 145.1, 135.9, 129.3, 128.6, 128.5, 127.7, 126.4, 99.4, 








6-Methyl-2-oxo-4-styryl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
4-4n: 1H NMR (DMSO-d6): δ 9.12 (s, 1H, NH), 7.53 (s, 1H, NH), 7.31 (m, 5H, ArH), 
6.38 (d, J=15.68 Hz, 1H, CH), 6.20 (dd, J=15.68, 5.92 Hz, 1H, CH), 4.73 (m, 1H, CH), 
4.08 (m, 2H, CH2), 2.20 (s, 3H, CH3), 1.19 (t, J=6.96 Hz, 3H, CH3). 13C NMR (DMSO-
d6):165.1, 152.4, 148.4, 136.2, 130.0, 128.5, 128.0, 127.5, 126.2, 97.7, 59.1, 51.8, 17.6, 












5,6-Diphenyl-2-thioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid ethyl ester 4-
5a: 1H NMR (DMSO-d6): δ 9.64 (s, 1H, NH), 9.43 (s, 1H, NH), 7.38-7.18 (m, 8H, ArH), 
7.01 (m, 2H, ArH), 5.15 (m, 1H, CH), 4.00 (q, J=6.97 Hz, 2H, OCH2), 0.94 (t, J=6.97 Hz, 
3H, CH3). 13C NMR (DMSO-d6): 173.1, 161.9, 141.0, 135.5, 128.4, 127.9, 127.8, 127.7, 
127.3, 126.8, 124.4, 118.8, 61.0, 59.1, 13.0. HRMS (EI): Calcd for C19H18N2O2S: 










2-Oxo-5,6-diphenyl-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid ethyl ester 4-5b: 
1H NMR (DMSO-d6): δ 8.42 (s, 1H, NH), 7.58 (s, 1H, NH), 7.31-7.19 (m, 8H, ArH), 
6.98 (m, 2H, ArH), 5.13 (m, 1H, CH), 3.94 (q, J=6.97 Hz, 2H, CH2), 0.88 (t, J=6.97 Hz, 
3H, CH3). 13C NMR (DMSO-d6): 162.8, 152.4, 142.5, 136.8, 128.6, 128.5, 127.9, 127.5, 
127.0, 126.0, 118.6, 61.0, 60.0, 13.2. HRMS (EI): Calcd for C19H18N2O3: 322.1317, 















5c: 1H NMR (DMSO-d6): δ 13.90 (s, 1H, COOH), 9.19 (s, 1H, NH), 8.38 (s, 1H, NH), 
7.66(m, 1H, ArH), 6.44(m, 1H, ArH), 6.32(m, 1H, ArH), 4.97 (m, 1H, CH), 1.95 (s, 3H, 
CH3). 13C NMR (DMSO-d6): 173.7, 163.2, 152.7, 143.4, 122.6, 118.8, 110.7, 107.8, 53.6, 










6-Ethyl-5-phenyl-2-thioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid 4-5d: 1H 
NMR (DMSO-d6): δ 13.34 (s, 1H, COOH), 8.94 (s, 1H, NH), 8.75 (s, 1H, NH), 7.33-7.23 
(m, 5H, ArH), 4.14 (m, 1H, CH), 1.46-1.32 (m, 2H, CH2), 0.84 (t, J=7.32 Hz, 3H, CH3). 
13C NMR (DMSO-d6): 174.5, 163.1, 136.3, 128.1, 128.0, 127.4, 124.5, 120.4, 57.3, 26.8, 
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Crystal data and structure refinement for 2-(4-Phenyl-5-(pyridin-4-yl)-1H-imidazol-1-
yl)ethanol 
 
Identification code  2-(4-Phenyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)ethanol 
Empirical formula  C16 H15 N3 O 
Formula weight  265.31 
Temperature  273(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.7569(6) Å α= 74.5690(10)°. 
 b = 12.5075(8) Å β= 86.6230(10)°. 
 c = 12.7422(8) Å γ= 81.9000(10)°. 
Volume 1331.55(15) Å3 
Z 4 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 560 
Crystal size 0.52 x 0.52 x 0.26 mm3 
Theta range for data collection 1.66 to 30.07°. 
Index ranges -12<=h<=12, -17<=k<=17, -17<=l<=17 
Reflections collected 20746 
Independent reflections 7726 [R(int) = 0.0324] 
Completeness to theta = 30.07° 98.9 %  
Absorption correction Sadabs 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7726 / 0 / 363 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0537, wR2 = 0.1368 
R indices (all data) R1 = 0.0745, wR2 = 0.1527 



















































































































Crystal Structure of 4-4m 


















   Crystal data and structure refinement for 6-Methyl-4-styryl-2-thioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylic acid ethyl ester 
. 
Identification code              6-Methyl-4-styryl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-   
                                                                        carboxylic acid ethyl ester                                                      
Empirical formula  C16 H18 N2 O2 S 
Formula weight  302.38 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 13.740(13) Å α= 90°. 
 b = 7.226(7) Å β= 110.58(2)°. 
 c = 17.198(15) Å γ= 90°. 
Volume 1598(3) Å3 
Z 4 
Density (calculated) 1.256 Mg/m3 
Absorption coefficient 0.208 mm-1 
F(000) 640 
Crystal size 0.234 x 0.234 x 0.078 mm3 
Theta range for data collection 2.35 to 24.00°. 
Index ranges -14<=h<=15, -8<=k<=8, -19<=l<=19 
Reflections collected 7802 
Independent reflections 2505 [R(int) = 0.1194] 
Completeness to theta = 24.00° 99.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2505 / 0 / 200 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.1042, wR2 = 0.2441 
R indices (all data) R1 = 0.1498, wR2 = 0.2755 
Largest diff. peak and hole 0.655 and -0.442 e.Å-3 
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